Published in Cancer on June 15, 2001
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet (2009) 3.99
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 2.69
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 1.73
Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. World J Surg (2009) 1.73
HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer (2004) 1.60
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer (2005) 1.59
Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Virchows Arch (2006) 1.49
Survival of MUTYH-associated polyposis patients with colorectal cancer and matched control colorectal cancer patients. J Natl Cancer Inst (2010) 1.48
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics (2012) 1.39
Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A (2013) 1.35
Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer (2013) 1.30
Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol (2006) 1.24
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov (2015) 1.24
Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol (2009) 1.23
High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer (2008) 1.20
Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 1.17
Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol (2010) 1.12
Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer (2013) 1.03
SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res (2009) 1.02
Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol (2003) 1.02
Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark (2006) 1.01
High lymph node yield is related to microsatellite instability in colon cancer. Ann Surg Oncol (2011) 1.00
Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer (2002) 1.00
Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol (2014) 1.00
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget (2015) 0.98
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (2010) 0.98
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer (2009) 0.98
Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer (2011) 0.97
Proximal versus distal hyperplastic polyps of the colorectum: different lesions or a biological spectrum? J Clin Pathol (2004) 0.97
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. BMC Cancer (2008) 0.95
Diagnosing Lynch syndrome: is the answer in the mouth? Gut (2003) 0.95
Hereditary nonpolyposis colorectal cancer (Lynch syndrome): criteria for identification and management. Dig Dis Sci (2005) 0.94
Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol (2015) 0.91
Analysis of colorectal cancer morphology in relation to sex, age, location, and family history. J Gastroenterol (2012) 0.91
HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia (2014) 0.90
Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer. Am J Surg Pathol (2008) 0.89
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
[Molecular pathology in hereditary colorectal cancer. Recommendations of the Collaborative German Study Group on hereditary colorectal cancer funded by the German Cancer Aid (Deutsche Krebshilfe)]. Pathologe (2004) 0.87
Clinical significance of microsatellite instability in colorectal cancer. Langenbecks Arch Surg (2013) 0.87
Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam Cancer (2013) 0.86
Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol (2010) 0.86
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer (2016) 0.85
Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.85
Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. J Natl Cancer Inst (2016) 0.85
Review of histopathological and molecular prognostic features in colorectal cancer. Cancers (Basel) (2011) 0.85
Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. J Clin Pathol (2006) 0.85
Clinicopathological analysis of colorectal cancer: a comparison between emergency and elective surgical cases. World J Surg Oncol (2013) 0.84
Genomic instability and carcinogenesis: an update. Curr Genomics (2008) 0.84
Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency. Int J Clin Exp Med (2015) 0.83
Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor? Dis Colon Rectum (2015) 0.83
Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) (2015) 0.83
Colorectal cancer susceptibility loci in a population-based study: Associations with morphological parameters. Am J Pathol (2010) 0.83
Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. World J Gastroenterol (2013) 0.83
Relationships of tumor inflammatory infiltration and necrosis with microsatellite instability in colorectal cancers. World J Gastroenterol (2005) 0.83
Immunology and the Lynch syndrome. Gastroenterology (2008) 0.82
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer (2016) 0.81
Microsatellite instability screening should be done for right-sided colon cancer patients less than 60 years of age. Int J Colorectal Dis (2009) 0.81
The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci (2016) 0.80
Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer (2016) 0.80
Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers. PLoS One (2013) 0.80
Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget (2016) 0.79
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer (2016) 0.79
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol (2016) 0.79
T([20]) repeat in the 3'-untranslated region of the MT1X gene: a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer. Int J Colorectal Dis (2011) 0.79
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl Lung Cancer Res (2015) 0.78
Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol (2017) 0.78
Lynch syndrome: clinical, pathological, and genetic insights. Langenbecks Arch Surg (2012) 0.78
Intestinal lymphatic vasculature: structure, mechanisms and functions. Nat Rev Gastroenterol Hepatol (2017) 0.78
Prognostic value of colorectal cancer biomarkers. Cancers (Basel) (2011) 0.77
Clinical and pathological tools for identifying microsatellite instability in colorectal cancer. Croat Med J (2012) 0.77
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. J Gastrointest Oncol (2016) 0.77
Cancer in Jews: introduction and overview. Fam Cancer (2004) 0.77
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal? Oncotarget (2015) 0.76
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Sci Rep (2015) 0.76
Efficient and reproducible identification of mismatch repair deficient colon cancer: validation of the MMR index and comparison with other predictive models. BMC Clin Pathol (2013) 0.76
Fas ligand expression in lynch syndrome-associated colorectal tumours. Pathol Oncol Res (2009) 0.75
Systematic evaluation of immune regulation and modulation. J Immunother Cancer (2017) 0.75
Integrative Omics Analysis Reveals Post-Transcriptionally Enhanced Protective Host Response in Colorectal Cancers with Microsatellite Instability. J Proteome Res (2015) 0.75
MUTYH the base excision repair gene family member associated with colorectal cancer polyposis. Gastroenterol Hepatol Bed Bench (2013) 0.75
The molecular basis of rectal cancer. Clin Colon Rectal Surg (2015) 0.75
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology (2017) 0.75
Colorectal clinical trials: what is on the horizon? Future Oncol (2016) 0.75
Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol (2016) 0.75
Semiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responses. BMC Cancer (2011) 0.75
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer (2016) 0.75
Spontaneous regression of transverse colon cancer: a case report. Surg Case Rep (2017) 0.75
[Molecular pathogenesis. Its importance in targeted therapy in colorectal cancer]. Pathologe (2008) 0.75
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. Biomed Res Int (2017) 0.75
Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers. J Gastrointest Cancer (2017) 0.75
Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. Fam Cancer (2014) 0.75
Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology (2017) 0.75
Catching goldfish: quality in qualitative research. J Health Serv Res Policy (1998) 34.08
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Qualitative research methods in health technology assessment: a review of the literature. Health Technol Assess (1998) 9.45
Information needs and decisional preferences in women with breast cancer. JAMA (1997) 7.46
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ (1993) 7.14
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet (1991) 6.61
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A (1987) 3.99
Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer (1993) 3.86
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology (1993) 3.76
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Conversion of diploidy to haploidy. Nature (2000) 3.28
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res (1994) 3.25
Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer (1998) 2.91
Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med (1966) 2.86
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst (1992) 2.82
A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer (1997) 2.53
Breast cancer family history as a risk factor for early onset breast cancer. Breast Cancer Res Treat (1988) 2.51
Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J Clin Microbiol (1998) 2.47
Comparison of physical treatments versus a brief pain-management programme for back pain in primary care: a randomised clinical trial in physiotherapy practice. Lancet (2005) 2.43
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res (1994) 2.39
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
c-mos proto-oncogene RNA transcripts in mouse tissues: structural features, developmental regulation, and localization in specific cell types. Mol Cell Biol (1987) 2.35
Screening for enteropathogenic Escherichia coli in infants with diarrhea by the fluorescent-actin staining test. Infect Immun (1991) 2.35
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet (1993) 2.33
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
Two infant vision screening programmes: prediction and prevention of strabismus and amblyopia from photo- and videorefractive screening. Eye (Lond) (1996) 2.25
Surgically induced necrotising sclerokeratitis (SINS)--precipitating factors and response to treatment. Br J Ophthalmol (1992) 2.22
Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregation analysis. J Natl Cancer Inst (1983) 2.21
Genetic instability of microsatellites in endometrial carcinoma. Cancer Res (1993) 2.20
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet (2004) 2.10
MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet (2000) 2.00
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Facial dyskinesia: a 16-year follow-up study. Br J Psychiatry (1991) 1.94
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med (1993) 1.91
Familial atypical multiple mole-melanoma syndrome. J Med Genet (1978) 1.88
Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychiatry (1998) 1.86
The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2001) 1.84
The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab (1997) 1.82
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Cancer family "G" revisited: 1895-1970. Cancer (1971) 1.81
The differential assessment of children's attention: the Test of Everyday Attention for Children (TEA-Ch), normative sample and ADHD performance. J Child Psychol Psychiatry (2001) 1.80
Rectal cancer in FAP patient after sulindac. Lancet (1994) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet (1998) 1.77
Ehlers-Danlos syndrome and "congenital" arteriovenous fistulae. A clinicopathologic study of a family. JAMA (1965) 1.77
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet (1993) 1.66
The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia (2000) 1.62
Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA (1999) 1.61
A follow-up study of colonic epithelial proliferation as a biomarker ina Native-American family with hereditary nonpolyposis colon cancer. J Natl Cancer Inst (1991) 1.57
Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol (1998) 1.55
What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol (1998) 1.55
Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev (2003) 1.54
Natural history of hereditary cancer of the breast and colon. Cancer (1982) 1.53
Symptom priority ranking in the care of gastroesophageal reflux: a review of 1,850 cases. Dig Dis (1999) 1.53
An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? Am J Hum Genet (1999) 1.52
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer (1985) 1.51
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg (1999) 1.51
Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J (1968) 1.50
Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer (1978) 1.49
Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res (1994) 1.49
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res (1997) 1.49
Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC. Cancer (1998) 1.48
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer (1985) 1.48
Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer (1996) 1.48
Inter-rater reliability of electron beam computed tomography to detect coronary artery calcification. Am J Card Imaging (1996) 1.47
A new polymerase chain reaction-based method for the detection of T-cell clonality in patients with possible cutaneous T-cell lymphoma. Arch Dermatol (1999) 1.47
The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol (1997) 1.46
A laparoscopic intraperitoneal onlay mesh technique for the repair of an indirect inguinal hernia. Ann Surg (1994) 1.46
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
Hereditary proximal colonic cancer. Dis Colon Rectum (1978) 1.45
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet (1996) 1.45
The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med (1981) 1.45
Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ (1990) 1.44
Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol (1982) 1.43